Global C1 Inhibitors Market Will Hit 9800 Millions By 2026, CAGR 18.6% – Facts & Factors
The global C1 inhibitors market was valued at USD 3300 million in 2019 and is expected to surpass USD 9800 million by 2026, registering a CAGR of 18.6% during the forecast period (2020-2026), as highlighted in a report published by Facts & Factors.
Browse Complete Report: https://www.fnfresearch.com/c1-inhibitors-market
C1 inhibitors are a type of protease inhibitor that is derived from the protein serpin. They are also known as C1 esterase inhibitors; however, unlike other members of the protein tree, they have both C-terminal and N-terminal domains. These inhibitors essentially aid in lowering the complement system’s self-consciousness in order to prevent damage and maintain functionality. It is an FXIIa inhibitor that can aid in blood coagulation, the production of kinins or fibrinolysis, and the activation of the complement system.
The rising prevalence of hereditary angioedema (HAE) diseases, as well as the preferred mode of treatment for prophylactic-based disorders, are expected to drive market growth during the forecast period. Furthermore, several influential studies have indicated that the use of C1 inhibitors will drive market growth even further.
Furthermore, growing awareness of the effectiveness of C1 inhibitors and their ability to prevent heart attacks will drive market growth. The use of C1 inhibitors as a short-term treatment for prophylactic diseases drives global demand for this product. However, a number of factors such as misdiagnosis, expensive medicines, and longer reimbursement times are expected to limit market growth.
Key Market Players:
Viropharma Biologics, Inc., Ionis Pharmaceuticals, Inc., iBio, Inc., Sanquin, and BioCryst Pharmaceuticals are among the key players in the global C1 inhibitors market.
On the basis of source, the C1 inhibitor market can be divided into two categories: human-derived and recombinantly derived. The human-derived C1 inhibitor segment is further subdivided into CINRYZE, Berinert, and HAEGARDA, whereas the recombinant-derived segment is further subdivided into Ruconest.
On the basis of mode of administration, the C1 inhibitors market can be divided into intravenous and subcutaneous segments. Doctors’ increasing use of the subcutaneous route of administration, as well as Ruconest’s improved availability, fuel the C1 inhibitor market. As a result, the subcutaneous mode of administration is expected to generate the most market revenue.
- During the forecast period, North America is expected to thrive.
In terms of global revenue collection, North America is expected to recoup the largest market share during the forecast period. Factors contributing to the region’s market growth include increased awareness of HAE treatment protocols and expanded support for reimbursement support from governmental agencies. Furthermore, the region’s well-established healthcare infrastructure and improved healthcare access will contribute to the growth of the global C1 inhibitors market.
Global C1 Inhibitors Market: By Regional Segment Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of MEA
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.